Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives Average Rating of "Buy" from Analysts

Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS - Get Free Report) have been given an average recommendation of "Buy" by the six brokerages that are covering the stock, Marketbeat.com reports. Five analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $25.20.

A number of brokerages recently weighed in on ATXS. Evercore ISI upgraded Astria Therapeutics to a "strong-buy" rating in a report on Wednesday, August 14th. Wedbush reaffirmed an "outperform" rating and set a $22.00 price target on shares of Astria Therapeutics in a research note on Tuesday, August 13th. HC Wainwright reissued a "buy" rating and issued a $16.00 price objective on shares of Astria Therapeutics in a research note on Friday, September 27th. Oppenheimer upped their target price on shares of Astria Therapeutics from $25.00 to $26.00 and gave the company an "outperform" rating in a research report on Tuesday, August 13th. Finally, TD Cowen began coverage on Astria Therapeutics in a research report on Monday, July 29th. They issued a "buy" rating and a $35.00 price target for the company.

Astria Therapeutics Stock Performance

Shares of NASDAQ ATXS traded up $0.07 during midday trading on Wednesday, hitting $12.06. 216,955 shares of the company traded hands, compared to its average volume of 636,392. Astria Therapeutics has a 12-month low of $4.26 and a 12-month high of $16.90. The stock has a 50-day moving average price of $11.57 and a 200 day moving average price of $10.49. The firm has a market cap of $662.25 million, a P/E ratio of -5.17 and a beta of 0.71.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last announced its quarterly earnings data on Monday, August 12th. The biotechnology company reported ($0.43) earnings per share for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.05). As a group, equities analysts expect that Astria Therapeutics will post -1.72 earnings per share for the current year.

Institutional Trading of Astria Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of ATXS. SG Americas Securities LLC acquired a new position in Astria Therapeutics in the 3rd quarter valued at $155,000. Cubist Systematic Strategies LLC acquired a new stake in Astria Therapeutics in the 2nd quarter valued at about $2,561,000. Nantahala Capital Management LLC purchased a new position in shares of Astria Therapeutics during the 2nd quarter worth approximately $6,142,000. Susquehanna Fundamental Investments LLC purchased a new position in Astria Therapeutics during the second quarter worth $400,000. Finally, Millennium Management LLC lifted its position in shares of Astria Therapeutics by 13.5% in the second quarter. Millennium Management LLC now owns 1,842,063 shares of the biotechnology company's stock valued at $16,763,000 after acquiring an additional 218,518 shares in the last quarter. 98.98% of the stock is currently owned by institutional investors and hedge funds.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.